ResMed shares fell 9.1% on Friday after its results disclosed weaker operating margin and cash generation, alongside unchanged full-year guidance. These offer plausible reasons for disappointment, but the specific catalyst remains unidentified; the results are confirmed, while that explanation is an inference.
The decline was 4.8x the typical daily move of 1.9%, and its largest fall since 24 June 2024. Trading volume was 2.9x its recent daily average. Covered health care equipment peers fell 3.3% at the median, while the broad market fell 1.8%, suggesting wider selling also contributed.
ResMed earnings outpaced operating profit
The quarter ended September brought revenue of $1.4 billion, up 5.9% from a year earlier but down 3.3% against the previous quarter. Operating income rose 1.4%, substantially slower than sales.
| Quarterly measure | Latest result | Year-earlier result |
|---|---|---|
| Operating margin | 32.0% | 33.4% |
| Operating cash flow | $422.4 million | $457.3 million |
| Free cash flow | $373.7 million | $414.4 million |
The release shows research and development spending and administrative costs increasing faster than revenue. Net income grew faster than operating profit, helped by a gain on the MatrixCare disposal. That makes headline earnings growth a less direct measure of recurring operating progress.
Operating cash flow fell 7.6%. The cash statement shows larger inventory and prepaid-asset outflows, partly offset by other working-capital movements. Disposal proceeds were investing cash flows, distinct from cash generated by operations.
The strongest alternative interpretation is that underlying demand remained healthy. ResMed cited growth in sleep devices and masks, while gross margin improved. The disposal affected reported revenue comparisons, and unchanged guidance was no forecast cut. Those details weaken any claim that the sell-off establishes a deterioration in demand.
Cash generation matters for model value
The past year’s free-cash-flow margin movement, if sustained, means model value falls 16.4%. Under the separate lower-growth scenario, model value falls 24.4%, a larger effect. These are model values under stated assumptions, not a comparison with the share price.
Recovery in both, alongside continued sleep-product demand, would challenge it. ResMed’s full company analysis provides the longer financial history.